• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Efruxifermin improves fibrosis in patients with metabolic dysfunction-associated steatohepatitis

byNeel MistryandTeddy Guo
September 17, 2025
in Chronic Disease, Gastroenterology
Reading Time: 2 mins read
Fatty liver disease collage: an engraved liver dotted with pale fat droplets beside a tray of three capped blood tubes
Share on FacebookShare on TwitterShare on LinkedIn

1. Efruxifermin 50 mg once-weekly significantly improved fibrosis at 96 weeks versus placebo.

2. MASH resolution without worsened fibrosis was greater in the efruxifermin group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Efruxifermin is a fibroblast growth factor analogue used for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Patients with MASH and advanced fibrosis have limited therapeutic options. As such, effective long-term therapies are needed. This randomized controlled trial aimed to evaluate the safety and efficacy of efruxifermin over 96 weeks in adults with biopsy-confirmed MASH and stage F2–F3 fibrosis. The primary outcome of this study was improvement in liver fibrosis without worsening of MASH, while key secondary outcome was resolution of MASH. According to study results, efruxifermin 50 mg led to significantly greater improvements in fibrosis compared with placebo, with acceptable safety and tolerability. Although this study was well done, it was limited by a small sample size and short follow-up period.

Click to read the study in The Lancet

Relevant Reading: Efruxifermin in Compensated Liver Cirrhosis Caused by MASH

RELATED REPORTS

ERX1000 plus semaglutide increased weight loss and metabolic measures in diet-induced obese mice

Investigational retatrutide reduced knee osteoarthritis pain and body weight versus placebo in adults with obesity

FDA approvedFor obesity: Foundayo (orforglipron), Apr 1, 2026→

In-depth [randomized controlled trial]: Between Mar 22, 2021, and Feb 7, 2022, 747 patients were assessed for eligibility across 41 centers in the USA. Included were patients aged ≥ 18 years with biopsy-confirmed MASH, a non-alcoholic fatty liver disease (NAFLD) activity score ≥ 4, and stage F2 or F3 fibrosis. Altogether, 115 patients (42 in placebo, 37 in efruxifermin 28 mg, and 36 in efruxifermin 50 mg) were included in the final analysis. The primary outcome of improved fibrosis without worsening of MASH was significantly greater in with 50 mg compared to placebo (49% vs. 19%, p=0.0030). Patient in efruxifermin 28 mg also had improved fibrosis without statistical significance (30% vs. 19%, p=0.19). The secondary outcome of MASH resolution without fibrosis worsening was more frequent among efruxifermin-treated patients versus placebo (75% in 50 mg vs. 24% in placebo, p<0.0001). Findings from this study suggest that efruxifermin shows promise as an effective therapy for improving fibrosis and MASH outcomes in patients with advanced disease.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic liver diseasecirrhosisEfruxiferminhepatologyliver cirrhosisliver diseaseMASHmetabolic dysfunction-associated steatohepatitisobesity
Previous Post

Measurement-based care may result in accelerated time to response and remission in major depressive disorder

Next Post

Implementation of a structure point-of-care ultrasound protocol for patients hospitalized with undifferentiated dyspnea may reduce length of stay

RelatedReports

A collection of pharmaceutical items including a blister pack of tablets, a pen-like device, and several blank labels or strips, suggesting medication for obesity management.
2MM Trial Briefs

ERX1000 plus semaglutide increased weight loss and metabolic measures in diet-induced obese mice

November 17, 2026
Knee osteoarthritis collage: a calm older man with a gray beard, a knee joint inset with teal cartilage and a knee brace
Endocrinology

Investigational retatrutide reduced knee osteoarthritis pain and body weight versus placebo in adults with obesity

November 17, 2026
Obesity measurement collage: a bathroom scale with a blank dial, a loose cloth measuring tape, an apple and a pear
Chronic Disease

Obesity associated with higher early-onset cancer risk among young Korean adults

November 13, 2026
Obesity treatment collage: a bathroom scale with a blank dial, a coiled tape measure and a bowl of fresh vegetables
2MM Trial Briefs

Once-monthly bofanglutide maintained weight loss over 24 weeks in topline phase 3 results

November 5, 2026
Next Post
Heart health collage: an engraved heart on a blue paper circle beside a sapling in a clay pot and a small watering can

Implementation of a structure point-of-care ultrasound protocol for patients hospitalized with undifferentiated dyspnea may reduce length of stay

2 Minute Medicine AI Roundup editorial illustration

2MM: AI Roundup –Dermatology accuracy, faster drug discovery, heart disease detection, and global medical training [September 11th,  2025]

Anesthesia collage: a clear face mask attached to a rubber breathing bag, a fingertip pulse oximeter and a surgical cap

Midazolam reduces respiratory variability in women with fibromyalgia compared with S-ketamine

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Removing Race and Ethnicity From Dialysis Mortality Risk Adjustment Changes Facility Performance Rankings
  • AI Model Shows Promise in Predicting PTSD Risk Following Trauma
  • 2 Minute Medicine Rewind November 16, 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.